Claims for Patent: 10,927,117

Summary for Patent: 10,927,117

Title:	Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydrop- yrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Abstract:	The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydrop- yrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Inventor(s):	Wang; Zhiwei (Beijing, CN), Guo; Yunhang (Beijing, CN), Shi; Gongyin (Beijing, CN)
Assignee:	BEIGENE SWITZERLAND GMBH (Basel, CH)
Application Number:	16/325,447
Patent Claims:	1. A crystalline form of Compound 1, ##STR00030## wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2 .theta. angle values at 14.8.+-.0.2.degree., 15.6.+-.0.2.degree., 16.4.+-.0.2.degree. and 21.4.+-.0.2.degree.. 2. The crystalline form of claim 1, wherein the crystalline form is an anhydrate. 3. The crystalline form of claim 1, having an X-ray powder diffraction pattern: a) further comprising diffraction peaks having 20 angle values at 12.2.+-.0.2.degree., 12.9.+-.0.2.degree.; b) further comprising diffraction peaks having 20 angle values at 12.2.+-.0.20, 12.9.+-.0.2.degree., 17.7.+-.0.2.degree., 18.5.+-.0.2.degree. and 20.7.+-.0.2.degree.; or c) substantially similar to FIG. 1. 4. The crystalline form of claim 2, wherein the crystalline form has a melting point of 139.+-.2.degree. C. (onset temperature) or wherein the crystalline form has a differential scanning calorimetry thermogram substantially similar to FIG. 2. 5. A method of preparing the crystalline form of claim 2, comprising the steps of: a) dissolving Compound 1 in EtOAc, adding hexane, and obtaining the crystalline form of Compound 1; b) dissolving Compound 1 in an organic solvent, adding water and obtaining the crystalline form of Compound 1, wherein the organic solvent is selected from acetone or DMAc (N,N-dimethylacetaminde); c) dissolving the crystalline form of claim 1 in an organic solvent, adding water, and obtaining the crystalline form of Compound 1, wherein the organic solvent is selected from acetone or DMAc; d) dissolving Compound 1 in an organic solvent, adding n-heptane, and obtaining the crystalline form of Compound 1, wherein the organic solvent is selected from EtOAc, DCM, toluene or 2-MeTHF (2-methyltetrahydrofuran); e) dissolving the crystalline form of claim 1 in an organic solvent, adding n-heptane, and obtaining the crystalline form of Compound 1, wherein the organic solvent is selected from EtOAc, DCM, toluene or 2-MeTHF; f) dissolving Compound 1 in acetone or EtOAc to obtain a solution, placing the solution into n-heptane, evaporating at room temperature, and obtaining the crystalline form of Compound 1; or g) dissolving the crystalline form of claim 1 in acetone or EtOAc to obtain a solution, placing the solution into n-heptane, evaporating at room temperature, and obtaining the crystalline form of Compound 1. 6. A pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of claim 1, and a pharmaceutically acceptable excipient.